AR113345A1 - ANTI-TRANSTIRETIN ANTIBODIES - Google Patents

ANTI-TRANSTIRETIN ANTIBODIES

Info

Publication number
AR113345A1
AR113345A1 ARP180102878A ARP180102878A AR113345A1 AR 113345 A1 AR113345 A1 AR 113345A1 AR P180102878 A ARP180102878 A AR P180102878A AR P180102878 A ARP180102878 A AR P180102878A AR 113345 A1 AR113345 A1 AR 113345A1
Authority
AR
Argentina
Prior art keywords
ttr
antibodies
transtiretin
accumulation
amyloidosis
Prior art date
Application number
ARP180102878A
Other languages
Spanish (es)
Inventor
Tarlochan S Nijjar
Jeffrey N Higaki
Robin Barbour
Svetlana Alexander
Joshua Reginald Salmans
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of AR113345A1 publication Critical patent/AR113345A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente provee anticuerpos que se unen específicamente a transtiretina (TTR). Los anticuerpos pueden ser utilizados para tratar o efectuar la profilaxis de enfermedades o trastornos asociados con acumulación de TTR o acumulación de depósitos de TTR (por ej. amiloidosis por TTR). Los anticuerpos también pueden ser utilizados para diagnosticar amiloidosis por TTR e inhibir o reducir la agregación de TTR, y para monitorear la eficacia de terapias contra TTR, entre otras aplicaciones.The present provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used to treat or effect prophylaxis of diseases or disorders associated with accumulation of TTR or accumulation of TTR deposits (eg, TTR amyloidosis). Antibodies can also be used to diagnose TTR amyloidosis and inhibit or reduce TTR aggregation, and to monitor the efficacy of TTR therapies, among other applications.

ARP180102878A 2017-10-06 2018-10-05 ANTI-TRANSTIRETIN ANTIBODIES AR113345A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762569436P 2017-10-06 2017-10-06

Publications (1)

Publication Number Publication Date
AR113345A1 true AR113345A1 (en) 2020-04-22

Family

ID=70465591

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102878A AR113345A1 (en) 2017-10-06 2018-10-05 ANTI-TRANSTIRETIN ANTIBODIES

Country Status (1)

Country Link
AR (1) AR113345A1 (en)

Similar Documents

Publication Publication Date Title
CU20200021A7 (en) ANTI-TRANSTIRETIN ANTIBODIES
CO2017008476A2 (en) Anti-transthyretin antibodies
CO2017008482A2 (en) Anti-transthyretin antibodies
CO2017008469A2 (en) Anti-transthyretin antibodies
CL2022001189A1 (en) Antibodies to cd40. (application divisional n° 2017003427)
CU20170052A7 (en) ANTIBODY MOLECULES THAT JOIN PD-L1
ECSP19044183A (en) (AZA) INDOL-, BENZOTHIOPHEN, AND BENZOFURAN-3-SULFONAMIDES
BR112017024877A2 (en) anti-cd38 antibody and its use in the treatment of light chain amyloidosis and other cd38 positive haematological malignancies
BR112018010464A8 (en) topical pharmaceutical formulations to treat related inflammatory conditions
UY36032A (en) ANTIBODY MOLECULES THAT JOIN LAG-3 AND USES OF THE SAME
WO2018007924A3 (en) Anti-transthyretin antibodies
MX2020003783A (en) Antibody molecules to cd138 and uses thereof.
ZA201906100B (en) Combination of a ppar agonist with a fxr agonist
WO2018007923A3 (en) Anti-transthyretin antibodies
AR113345A1 (en) ANTI-TRANSTIRETIN ANTIBODIES
CL2020000586A1 (en) Modulators of enac expression.
AR103549A1 (en) ANTI-TRANSTIRETINE ANTIBODIES
EA202090898A1 (en) ANTITRANSTYRETIN ANTIBODIES
AR103548A1 (en) ANTI-TRANSTIRETINE ANTIBODIES
CO2021000349A2 (en) Complement Component 5 Antibody Molecules and Their Uses
CR20190329A (en) MODULATORS OF COMPLEMENT FACTOR Bi